Myovant Sciences Appoints Ryan Crowe as Vice President, Investor Relations

Rhea-AI Summary

Myovant Sciences has appointed Ryan Crowe as vice president of investor relations. He will oversee daily interactions with analysts and investors while developing a global investor relations program, reporting to Frank Karbe, president and CFO. Crowe brings over 15 years of experience from Pfizer, where he advanced the investor relations department. The company is positioning itself for commercial growth in prostate cancer and women’s health, with multiple product launches on the horizon. This strategic hire aims to strengthen Myovant's connection with the investment community.

Positive

• Ryan Crowe's extensive experience in investor relations from Pfizer may enhance communication and transparency with investors.
• Myovant is poised for growth with several upcoming product launches, potentially increasing its market presence.

Negative

• The transition may create temporary disruptions in investor relations as a new leadership style is implemented.
• There may be concerns regarding continuity and the adaptation of company culture with a new executive.

BASEL, Switzerland, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of Ryan Crowe as vice president, investor relations. In addition to managing day-to-day interactions with analysts and investors, Mr. Crowe will be responsible for developing and implementing a comprehensive and strategic global investor relations program. He will report to Frank Karbe, Myovant’s president and chief financial officer.

“We are delighted to welcome Ryan to Myovant,” said Mr. Karbe. “He brings a deep knowledge of the pharmaceutical industry and, combined with his extensive investor relations experience, will continue to strengthen Myovant’s relationship with the investment community.”

Mr. Crowe joins Myovant after nearly 16 years at Pfizer Inc., where he most recently served as senior director of investor relations and was responsible for conducting global investor relations activities for the company. Prior to his most recent role, he held positions of increasing responsibility on the Pfizer investor relations team as well as in Pfizer’s tax department.

“I am thrilled to join Myovant at this pivotal time,” said Mr. Crowe. “With compelling data and multiple potential upcoming launches across prostate cancer and women’s health, Myovant is poised to transition to a commercial-stage healthcare company and I look forward to regularly communicating our progress with the investment community.”

During Mr. Crowe’s tenure at Pfizer, the company’s investor relations program was consistently ranked among the top three in the pharmaceuticals sector by Institutional Investor magazine, based on a survey of institutional portfolio managers and analysts. Additionally, in 2020, he was recognized as the "Best IR Professional" amongst all pharmaceutical companies. He earned an undergraduate degree in commerce and engineering sciences from Drexel University and a master’s degree in business administration from the Leonard N. Stern School of Business at New York University.

About Myovant Sciences
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our lead product candidate, relugolix, is a once-daily, oral GnRH receptor antagonist. Relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Relugolix monotherapy tablet (120 mg) is under regulatory review in the U.S. for men with advanced prostate cancer. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website at www.myovant.com. Follow @Myovant on Twitter and LinkedIn.

Investor Contact:
Ryan Crowe
Vice President, Investor Relations
Myovant Sciences, Inc.
investors@myovant.com

Media Contact:
Albert Liao
Director, Corporate Communications
Myovant Sciences, Inc.
media@myovant.com

FAQ

Who is Ryan Crowe and what is his role at Myovant Sciences?

Ryan Crowe has been appointed as vice president of investor relations at Myovant Sciences, responsible for managing communications with analysts and investors.

What relevant experience does Ryan Crowe have?

Ryan Crowe previously worked at Pfizer for nearly 16 years, most recently as senior director of investor relations, where he managed global investor relations activities.

Why is Myovant Sciences focusing on investor relations?

Myovant is aiming to strengthen its relationship with the investment community as it prepares for commercial launches in prostate cancer and women’s health.

What products is Myovant Sciences looking to launch?

Myovant is gearing up for launches involving products related to prostate cancer and women's health, including its lead product candidate, relugolix.

What impact could the new VP of investor relations have on Myovant Sciences?

Ryan Crowe's appointment could lead to improved investor communication and potentially a more favorable perception of the company among investors.